Lupin Limited has recently informed exchanges about the launch of Mirabegron Extended-Release Tablets, 50 mg, in the United States, following U.S. FDA approval.
In the exchange filing, the company shared, “Mirabegron Extended-Release Tablets, 50 mg is a generic equivalent of Myrbetriq® Extended-Release Tablets, 50 mg of Astellas Pharma Global Development, Inc.
Mirabegron Extended-Release Tablets, 50 mg had estimated annual sales of USD 1,600 million in the U.S. (IQVIA MAT July 2024).”
Lupin Limited is a global pharmaceutical company headquartered in Mumbai, India, with products available in over 100 markets. Lupin manufactures pharmaceutical goods, such as branded and generic formulations, complex generics, biotechnology products and active pharmaceutical ingredients. Trusted by healthcare experts and customers worldwide, the firm has a significant presence in India and the United States in a variety of therapy areas, such as respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system and women’s health.